# An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

> **NCT02303444** · — · COMPLETED · sponsor: **Bayer** · enrollment: 667 (actual)

## Conditions studied

- Thyroid Neoplasms

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)
- **DRUG:** Other Multikinase inhibitors

## Key facts

- **NCT ID:** NCT02303444
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-08
- **Primary completion:** 2020-06-10
- **Final completion:** 2020-07-24
- **Target enrollment:** 667 (ACTUAL)
- **Last updated:** 2023-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02303444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02303444, "An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02303444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*